Hematopoiesis reconstitution and anti-tumor effectiveness of Pai-Neng-Da capsule in acute leukemia patients with haploidentical hematopoietic stem cell transplantation

Figure 2 Cumulative survival analysis according to treatment group. A: Relapse-free survival; B: Progression-free survival; C: Overall survival. The 3-year relapse-free survival for the Pai-Neng-Da (PND) group and non-PND group were 69.1% and 61.9%, respectively, P = 0.046. The 3-year progression-free survival for the PND group and non-PND group were 69.1% and 61.7%, respectively, P = 0.049. The 3-year overall survival for the PND group and non-PND group were 69.1% and 65.6%, respectively, P = 0.069.